Eutilex Co., Ltd.

Korea University Research and Business Foundation

Cha University Industry-academic Cooperation Foundation

Eun Hye Yoo

Young Ho Kim

Seung Hyun Lee

Byoung S Kwon

Kwang Hee Kim

Jin Kyung Choi

Sun Woo Im

Hyun Tae Son

Young Gyoon Chang

Bo Rim Yi

Jung Yun Lee

Ji Won Chung

Hyeon Soo Kim

Ji Hyung Chung

Min-Jeong Shin

Inhyeok Jeong

The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

Anticancer pharmaceutical composition containing IF1 as active ingredient

The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Chimeric antigen receptor that binds HLA-DR and CAR-T cell

Growing community of inventors

Seoul, South Korea

Eun Hye Yoo